Research To Practice | Oncology Videos

Latest Episodes:

Breast Cancer | Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Breast Cancer Jan 17, 2023

Show notes

Featuring perspectives from Dr Joyce O'Shaughnessy and Prof Peter Schmid, including the following topics:

Introduction: POSITIVE Trial — Temporary Interruption of Endocrine Therapy for Pregnancy (0:00)
Metastatic Breast Cancer — Dr O'Shaughnessy (7:44)
Localized Breast Cancer — Prof Schmid (41:25)

CME information and select publications

Acute Myeloid Leukemia | What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of Acute Myeloid Leukemia Jan 13, 2023

Show notes

Featuring perspectives from Drs Courtney DiNardo and Mark Levis, including the following topics:

Introduction (0:00)
Case: A man in his early 80s with newly diagnosed acute myeloid leukemia (AML) with significant comorbidities receives decitabine/venetoclax — Rebecca L Olin, MD, MSCE (7:36)
Cases: A man in his mid 50s after 7 + 3 and allogeneic stem cell transplantation (SCT) presents with myeloid sarcoma; a man in his late 70s after 7 + 3 and allogeneic SCT presents with myeloid sarcoma — Spencer H Bachow, MD and Ranju Gupta, MD (12:16)
Case: A man in his late 30s with core binding factor AML after induction CLAG-M with gemtuzumab ozogamicin followed by high-dose cytarabine x 4 — Anna Halpern, MD (18:10)
Case: A woman in her mid 60s with newly diagnosed del(5q) AML with monocytic differentiation and multiple mutations (GATA2, BCOR, NF1 and RUNX1) receives azacitidine and venetoclax — Bhavana (Tina) Bhatnagar, DO (31:05)
Selection of Therapy for Patients with AML (35:20)
Cases: A man in his early 50s with therapy-related AML with an MLL mutation who receives CPX-351; a man in his early 70s with secondary AML with an IDH mutation — Amany R Keruakous, MD, MS and Priya Rudolph, MD, PhD (41:42)
Case: A man in his early 70s with recurrent AML with an IDH2 mutation receives enasidenib and develops differentiation syndrome/disease progression — Dr Halpern (50:00)

CME information and select publications

Acute Myeloid Leukemia | Courtney D DiNardo, MD, MSCE Jan 13, 2023

Show notes

What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of Acute Myeloid Leukemia — Faculty Presentation 1: Selection of Therapy for Older and Younger Patients with Acute Myeloid Leukemia (AML) — Dr Courtney DiNardo

CME information and select publications

Acute Myeloid Leukemia | Andrew H Wei, MBBS, PhD Jan 13, 2023

Show notes

What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of Acute Myeloid Leukemia — Faculty Presentation 2: Treatment of AML with Targetable Mutations — Dr Andrew Wei

CME information and select publications

Gastroesophageal Cancers | Oncology Today with Dr Neil Love: Management of Gastroesophageal Cancers (Companion Faculty Lecture) Jan 12, 2023

Show notes

Featuring an interview with Dr Manish Shah, including the following topics:

Biologic rationale for targeting PD-1/PD-L1 in upper GI cancers (0:00)
Management of HER2-positive gastric cancers (6:38)
Activity and tolerability of therapies targeting claudin 18.2 for patients with GI malignancies (15:48)

CME information and select publications

Gastroesophageal Cancers | Oncology Today with Dr Neil Love: Management of Gastroesophageal Cancers Jan 12, 2023

Show notes

Featuring an interview with Dr Manish Shah, including the following topics:

Role of targeted and immunotherapy regimens for upper GI cancers (0:00)
Future of CAR T-cell therapy for patients with gastric cancer (11:26)
Case: A man in his mid 60s with HER2-positive gastroesophageal adenocarcinoma (15:59)
Case: A woman in her mid 70s with newly diagnosed HER2-negative, pMMR gastric cancer (29:57)
Case: A man in his mid 50s with dMMR, HER2-negative gastric cancer (37:32)

CME information and select publications

Multiple Myeloma | Addressing Current Questions and Controversies in the Management of Multiple Myeloma — What Clinicians Want to Know Jan 11, 2023

Show notes

Featuring perspectives from Drs Jesús Berdeja, Rafael Fonseca, Sagar Lonial, Robert Orlowski and Noopur Raje, including the following topics:

Front-Line Treatment of Multiple Myeloma (MM)
- Introduction (0:00)
- Case: A woman in her early 50s with newly diagnosed MM (NDMM) and 1q gain who presents with a pathologic fracture and receives daratumumab/RVd — Bhavana (Tina) Bhatnagar, DO (2:49)
- Cases: An otherwise healthy man in his late 80s with NDMM who is disinclined to undergo aggressive therapy and a transplant-ineligible woman in her late 70s with NDMM — Erik Rupard, MD and Hans Lee, MD (10:05)
- Dr Orlowski presentation (15:45)
Integration of Novel Therapies into the Management of Relapsed/Refractory MM
- Cases: A transplant-eligible man in his late 60s with well-controlled HIV-1 and standard-risk NDMM and a man in his late 60s with high-risk, t(4;14) multiregimen-refractory MM with travel limitations who receives belantamab mafodotin — Neil Morganstein, MD and Syed Farhan Zafar, MD (29:19)
- Cases: A woman in her early 70s who receives daratumumab, bortezomib and dexamethasone for relapsed MM 6 years after RVd followed by autologous stem cell transplant and maintenance bortezomib, and a man in his mid 50s with NDMM who received RVd followed by maintenance lenalidomide, which was discontinued by the patient after 1 year — Henna Malik, MD and Dr Rupard (35:50)
- Dr Fonseca presentation (41:57)
Current Role of Chimeric Antigen Receptor (CAR) T-Cell Therapy for MM
- Case: A man in his early 70s with NDMM who receives induction daratumumab/RVd — Spencer H Bachow, MD (52:27)
- Cases: A woman in her early 60s with relapsed MM and pathologic fractures who received induction daratumumab/Rd and palliative radiation therapy for bone disease, and a woman in her mid 70s with refractory MM 6 months after induction daratumumab/RVd lite — Dr Bhatnagar and Kimberly Ku, MD (57:00)
- Dr Raje presentation (1:01:12)
Bispecific Antibodies in the Treatment of MM
- Case: A man in his early 70s with t(4;14) NDMM who initiates RVd, which is put on hold to treat severe depression — Warren S Brenner, MD (1:14:38)
- Case: A woman in her mid 70s with multiregimen-refractory del(17p) MM who is considered for BCMA-directed therapy — Dr Bachow (1:16:28)
- Dr Berdeja presentation (1:22:18)
Other Investigational Novel Agents for MM
- Case: A woman in her mid 80s with congestive heart failure and t(4;14), t(11;14) and t(14;16) MM who receives dose-reduced RVd and develops chalazion eye toxicity — Jennifer L Dallas, MD (1:36:23)
- Dr Lonial presentation (1:39:34)

CME information and select publications

Hodgkin and Non-Hodgkin Lymphoma | Addressing Current Questions and Controversies in the Management of Hodgkin and Non-Hodgkin Lymphoma — What Clinicians Want to Know Jan 09, 2023

Show notes

Featuring perspectives from Drs Jonathan Friedberg, Brad Kahl, David Maloney, Loretta Nastoupil and Sonali Smith, including the following topics:

Diffuse Large B-Cell Lymphoma (DLBCL)
- Introduction (0:00)
- Case: A woman in her early 60s with DLBCL with renal and subcutaneous involvement — Erik Rupard, MD (2:36)
- Cases: An otherwise healthy woman in her mid 80s with an orbital mass diagnosed with Stage IE DLBCL and a man in his early 80s with Stage IIIB DLBCL, GCB type and LVEF 35% to 40% due to prior myocardial infarction and coronary artery disease — Bhavana (Tina) Bhatnagar, DO and Yanjun Ma, MD (7:10)
- Dr Friedberg presentation (11:54)
Follicular Lymphoma
- Case: A man in his late 60s with progressive Grade I/II follicular lymphoma after observation for many years — Neil Morganstein, MD (29:07)
- Case: A woman in her early 60s with Grade II follicular lymphoma who received bendamustine/rituximab and maintenance rituximab — Jennifer L Dallas, MD (33:11)
- Dr Nastoupil presentation (38:36)
Hodgkin Lymphoma
- Case: A woman in her early 80s with newly diagnosed classical Hodgkin lymphoma — Kapisthalam (KS) Kumar, MD(51:21)
- Cases: A woman in her late 30s with newly diagnosed classical Hodgkin lymphoma and a man in his early 60s with newly diagnosed Stage IV classical Hodgkin lymphoma who receives brentuximab/vedotin with AVD (doxorubicin/vinblastine/dacarbazine) — Susmitha Apuri, MD and Amany R Keruakous, MD, MS (55:21)
- Dr Smith presentation (1:10:17)
Chimeric Antigen Receptor (CAR) T-Cell Therapy for Non-Hodgkin Lymphoma
- Cases: A man in his late 50s who presents with a large cecal mass and mesenteric adenopathy and is diagnosed with "double hit" DLBCL and a woman in her early 70s with DLBCL treated with R-CHOP, now with progressive disease 6 months later — Vignesh Narayanan, MD and Rahul Gosain, MD (1:14:56)
- Case: A woman in her early 70s with rapid relapse after R-CHOP then R-ICE (rituximab/ifosfamide/carboplatin/etoposide) and ASCT who achieves a complete response with CAR T-cell therapy but experiences significant pancytopenias — John Yang, MD (1:22:10)
- Dr Maloney presentation (1:25:24)
Mantle Cell Lymphoma (MCL)
- Case: A man in his late 70s with high-risk relapsed MCL after BR and maintenance rituximab x 3 years — Raman Sood, MD (1:39:10)
- Case: A man in his mid 80s who received prior treatment for prostate cancer and presents with low-volume indolent MCL with a TP53 mutation — Spencer H Bachow, MD (1:42:47)
- Dr Kahl presentation (1:45:29)

CME information and select publications

Urothelial Bladder Cancer | Oncology Today with Dr Neil Love: Managing Metastatic Urothelial Bladder Cancer Jan 05, 2023

Show notes

Featuring an interview with Dr Scott Tagawa, including the following topics:

Sequencing therapies for patients with metastatic urothelial bladder cancer (UBC) (0:00)
Case: A man in his mid 80s with UBC with multiple lung and lymph node metastases (4:55)
Case: A woman in her mid 80s with metastatic UBC who is undergoing treatment with erdafitinib (46:21)
Case: A man in his mid 60s with FGFR-altered metastatic UBC (49:45)

CME information and select publications

Urothelial Bladder Cancer | Oncology Today with Dr Neil Love: Managing Metastatic Urothelial Bladder Cancer (Companion Faculty Lecture) Jan 05, 2023

Show notes

Featuring a slide presentation and related discussion from Dr Scott Tagawa, including the following topics: